Mustang Bio (MBIO) Total Liabilities (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Total Liabilities of $8.0 million for Q1 2026, down 29.33% year-over-year from $11.3 million in Q1 2025, and down 0.97% quarter-over-quarter from $8.1 million in Q4 2025.
Mustang Bio (MBIO) Total Liabilities (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Total Liabilities for 11 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 29.33% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (down 29.33% YoY), while the FY2025 annual figure was $8.1 million, down 38.82% from the prior year.
- Total Liabilities eased to $8.0 million in Q1 2026 per MBIO's latest filing, from $8.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $46.1 million in Q4 2022 and bottomed at $8.0 million in Q1 2026.
- Historically, Total Liabilities has averaged $22.1 million across 5 years, with a median of $16.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 387.62% — and 2023, when it slumped 62.8%.
- Mustang Bio's Total Liabilities stood at $46.1 million in 2022, then tumbled by 61.82% to $17.6 million in 2023, then retreated by 25.19% to $13.2 million in 2024, then tumbled by 38.82% to $8.1 million in 2025, then slipped by 0.97% to $8.0 million in 2026.
- Business Quant data shows MBIO's Total Liabilities at $8.0 million in Q1 2026, $8.1 million in Q4 2025, and $9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | 8.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Mn |
| Mar 31, 2026 | 7.99 Mn |
| Dec 31, 2025 | 8.06 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 10.15 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 13.18 Mn |
| Sep 30, 2024 | 15.85 Mn |
| Jun 30, 2024 | 16.85 Mn |
| Mar 31, 2024 | 19.54 Mn |
| Dec 31, 2023 | 17.62 Mn |
| Sep 30, 2023 | 16.56 Mn |
| Jun 30, 2023 | 15.37 Mn |
| Mar 31, 2023 | 43.79 Mn |
| Dec 31, 2022 | 46.15 Mn |
| Sep 30, 2022 | 44.51 Mn |
| Jun 30, 2022 | 39.90 Mn |
| Mar 31, 2022 | 39.63 Mn |
| Dec 31, 2021 | 12.77 Mn |
| Sep 30, 2021 | 12.49 Mn |